Methylation-based tumor marker STAMP-EP8 and its applications

The STAMP-EP8 tumor marker addresses the limitations of existing DNA methylation markers by utilizing specific methylation modifications to accurately detect tumors, enhancing sensitivity and specificity in diagnosing various cancer types.

JP7577791B2Active Publication Date: 2024-11-05SHANGHAI EPIPROBE BIOTECH CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2023093508
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-30
Filing Date
2023-06-06
Publication Date
2024-11-05
Estimated Expiration
2040-04-29

AI Technical Summary

Technical Problem

Existing tumor markers based on DNA methylation have low sensitivity and specificity, struggle with heterogeneous tumor cell populations, and lack uniform standards for clinical applications, leading to misdiagnosis and inadequate sensitivity in detecting tumor origins and metastasis.

Method used

Development of a tumor marker, STAMP-EP8, which utilizes specific DNA methylation modifications at CpG sites, including 5-methylation, 5-hydroxymethylation, and 5-formylation, and complementary sequences, to detect aberrant hypermethylation patterns in various tumor types using polynucleotides and detection reagents.

Benefits of technology

STAMP-EP8 provides high accuracy in distinguishing between tumor and normal tissues, enabling effective tumor detection across multiple cancer types, including hematological, gastrointestinal, respiratory, and nervous system tumors, with potential applications in tissue and fluid samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577791000009
    Figure 0007577791000009
  • Figure 0007577791000010
    Figure 0007577791000010
  • Figure 0007577791000011
    Figure 0007577791000011
Patent Text Reader

Abstract

To provide an isolated polynucleotide and a use thereof, wherein the isolated polynucleotide is the polynucleotide shown in SEQ ID NO:1 or a fragment or complementary nucleic acid thereof having a modified CpG site.SOLUTION: The present invention provides an isolated polynucleotide and a use thereof, wherein the isolated polynucleotide is the polynucleotide shown in SEQ ID NO:1 or a fragment or complementary nucleic acid thereof having a modified CpG site. Further provided are the use of the polynucleotide for preparing a tumor detection reagent or a kit, a preparation method therefor, a reagent and a use thereof, a kit, and a method for the in-vitro detection of the methylation profile of a sample.SELECTED DRAWING: Figure 12
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of disease diagnostic markers, and more specifically, the present invention relates to a tumor marker based on methylation modification, STAMP (Specific Tumor Aligned Methylation of Pan-cancer), and its applications. [Background technology]

[0002] The idea that tumors are genetic diseases has persisted in the field for decades. Several systematic large-scale sequencing studies of people have identified a significantly lower number of somatic mutations in cancer tissues than expected, suggesting that cancer is not simply a genetic disease.

[0003] In order to achieve tumor diagnosis, in recent years, many new tumor markers have been discovered and used in clinical diagnosis. Before 1980, tumor markers were mainly cell secretions such as hormones, enzymes, and proteins, for example, carcinoembryonic antigen (CEA), alpha-fetoprotein antigen (AFP), etc. are markers for many tumors such as gastric cancer and liver cancer, carbohydrate antigen 125 (CA125) can be used as a marker for cervical cancer, and prostate-specific antigen (PSA) can be used as a marker for prostate cancer; although such tumor markers are still used in clinical practice, their sensitivity and accuracy are difficult to meet clinical needs.

[0004] More and more evidence indicates that small changes in epigenetic regulation play a key role in tumors. Epigenetics is the study of heritable changes in gene function and ultimately resulting phenotypic changes without altering the DNA sequence of the gene. Epigenetics mainly includes biochemical processes such as DNA methylation, histone modification, and changes in microRNA levels. DNA methylation, one of the epigenetic mechanisms, refers to the process in vivo in which a methyl group is transferred to a specific base using S-adenosylmethionine (SAM) as a methyl donor under the catalysis of DNA methyltransferase (DMT). In mammals, DNA methylation mainly occurs at the C of 5'-CpG-3' to generate 5-methylcytosine (5mC).

[0005] Liquid biopsy technology is a technology for diagnosing and predicting tumors that uses circulating tumor cells or circulating tumor DNA in the blood as detection targets. This technology has many shortcomings: first, the sensitivity and specificity are not high enough; the tumor itself is very heterogeneous and contains multiple subtype cell populations; in clinical samples, especially blood samples, the proportion of tumor DNA is very small, making it difficult for existing tumor markers to meet the sensitivity of clinical needs and prone to misdiagnosis in clinical practice; second, one marker can only work on one or a few tumors, and the origin of DNA in blood is very complex, so existing tumor markers cannot deal with the origin and metastasis of complex tumors. Due to these complex circumstances, many DNA methylation tumor markers are difficult to have a unified standard when used in clinical applications, which severely affects the sensitivity and accuracy of the markers.

[0006] Although our previous studies have discovered several tumor markers based on methylation modifications, it is necessary to find more new tumor markers to provide more tools for tumor diagnosis. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] CN109971860A [Patent Document 2] CN105886657A Summary of the Invention [Problem to be solved by the invention]

[0008] It is an object of the present invention to provide a method for detecting tumors using DNA methylation modifications as tumor markers, utilizing abnormal hypermethylation at specific sites in the tumor. [Means for solving the problem]

[0009] In a first aspect, the present invention provides an isolated polynucleotide comprising: (a) a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 1; (b) a fragment of the polynucleotide of (a) in which at least one modified CpG site is present (e.g., 2 to 191, more particularly 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190); and / or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b) (e.g., a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 3).

[0010] In one preferred example, the modification includes a 5-methylation modification, a 5-hydroxymethylation modification, a 5-formylation modification, or a 5-carboxylation modification.

[0011] In another preferred embodiment, (b) includes the following in the above-mentioned polynucleotide fragment: bases 204 to 223 (including methylation sites 021 to 024) of SEQ ID NO: 1 or 2; bases 1 to 478 (including methylation sites 001 to 040) of SEQ ID NO: 1 or 2; bases 513 to 1040 (including methylation sites 041 to 077) of SEQ ID NO: 1 or 2; bases 1082 to 1602 (including methylation sites 078 to 114) of SEQ ID NO: 1 or 2; bases 1621 to 2117 (including methylation sites 115 to 153) of SEQ ID NO: 1 or 2; or bases 2160 to 2700 (including methylation sites 154 to 191) of SEQ ID NO: 1 or 2.

[0012] In a second aspect of the invention, there is provided an isolated polynucleotide corresponding to the sequence of the first aspect above, which is converted from the polynucleotide described above, except that the cytosine C at the modified CpG site is unchanged and the unmodified cytosine is converted to T or U.

[0013] In one preferred embodiment, it is converted from a polynucleotide corresponding to the first embodiment treated with bisulfite. In another preferred embodiment, the polynucleotide includes (d) a polynucleotide having a nucleotide sequence as shown in SEQ ID NO:2 or SEQ ID NO:4; (e) a fragment of the polynucleotide of (d) above, in which at least one modified CpG site (e.g., 2 to 191, more specifically, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190) is present.

[0014] In another preferred embodiment, in (e), the following are present in the above-mentioned polynucleotide fragment: bases at positions 204 to 223 (including methylation sites 021 to 024); bases at positions 1 to 478 (including methylation sites 001 to 040) of SEQ ID NO: 1 or 2; bases at positions 513 to 1040 (including methylation sites 041 to 077) of SEQ ID NO: 1 or 2; bases at positions 1082 to 1602 (including methylation sites 078 to 114) of SEQ ID NO: 1 or 2; bases at positions 1621 to 2117 (including methylation sites 115 to 153) of SEQ ID NO: 1 or 2; bases at positions 2160 to 2700 (including methylation sites 154 to 191) of SEQ ID NO: 1 or 2; bases at positions 2478 to 2497 (corresponding to methylation sites 021 to 024); bases at positions 2223 to 2700 of SEQ ID NO: 4 or 3 (corresponding to methylation sites 001 to 040); bases at positions 1661 to 2188 of SEQ ID NO: 4 or 3 (corresponding to methylation sites 041 to 077); bases at positions 1099 to 1619 of SEQ ID NO: 4 or 3 (corresponding to methylation sites 078 to 114); bases at positions 584 to 1080 of SEQ ID NO: 4 or 3 (corresponding to methylation sites 115 to 153); or bases at positions 1 to 541 of SEQ ID NO: 4 or 3 (corresponding to methylation sites 154 to 191).

[0015] In a third aspect of the present invention, there is provided the use of a polynucleotide as described in the first or second aspect for the preparation of a reagent or kit for tumor detection.

[0016] In one preferred example, the tumor includes, but is not limited to, blood system tumors such as leukemia, lymphoma, and multiple myeloma; gynecological and reproductive system tumors such as breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, and penile cancer; digestive system tumors such as esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, and gallbladder cancer; respiratory system tumors such as lung cancer and pleurioma; nervous system tumors such as glioma, neuroblastoma, and meningioma; head and neck cancers such as oral cancer, tongue cancer, laryngeal cancer, and nasopharyngeal cancer; urinary system tumors such as kidney cancer and bladder cancer; and skin and other system tumors such as skin cancer, melanoma, osteosarcoma, liposarcoma, and thyroid cancer.

[0017] In another preferred example, the tumor sample includes, but is not limited to, tissue samples, paraffin-embedded samples, blood samples, pleural fluid samples, bronchoalveolar lavage fluid samples, ascites and lavage fluid samples, bile samples, stool samples, urine samples, saliva samples, sputum samples, cerebrospinal fluid samples, cell smear samples, cervical smear or brush samples, tissue and cell biopsy samples.

[0018] In a fourth aspect of the present invention, there is provided a method for preparing a tumor detection reagent, the method comprising the steps of: providing a polynucleotide as described in the first or second aspect; designing a detection reagent for specifically detecting the modification status of a CpG site in the target sequence using the full length or a fragment of the polynucleotide as a target sequence; provided that the target sequence contains at least one (e.g., 2 to 191, more specifically, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190) modified CpG site; preferably, the detection reagent includes, but is not limited to, a primer and a probe.

[0019] In a fifth aspect of the present invention, there is provided a reagent or combination of reagents for specifically detecting the modification status of a CpG site in a target sequence, wherein the target sequence is a full length or a fragment of a polynucleotide as described in any one of the first or second aspects, and contains at least one (e.g. 2 to 191, more specifically 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190) modified CpG site.

[0020] In one preferred example, the reagent or combination of reagents targets (is designed based on) a gene sequence comprising the target sequence, and the gene sequence comprises a gene panel or group of genes.

[0021] In another preferred embodiment, the detection reagent includes a primer and a probe.

[0022] In another preferred embodiment, the primers are those shown in SEQ ID NOs:3 and 4; those shown in SEQ ID NOs:7 and 8; those shown in SEQ ID NOs:9 and 10; those shown in SEQ ID NOs:11 and 12; or those shown in SEQ ID NOs:13 and 14; or those shown in SEQ ID NOs:15 and 16.

[0023] In a sixth aspect of the present invention, there is provided a use of a reagent or a combination of reagents as described in the fifth aspect for preparing a kit for detecting tumors; preferably, said tumors include, but are not limited to, hematological tumors such as leukemia, lymphoma, multiple myeloma, etc.; gynecological and reproductive tumors such as breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, penile cancer, etc.; digestive tumors such as esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, gallbladder cancer, etc.; respiratory tumors such as lung cancer, pleurioma, etc.; nervous tumors such as glioma, neuroblastoma, meningioma, etc.; head and neck cancers such as oral cancer, tongue cancer, laryngeal cancer, nasopharyngeal cancer, etc.; urological tumors such as kidney cancer, bladder cancer, etc.; skin and other system tumors such as skin cancer, melanoma, osteosarcoma, liposarcoma, thyroid cancer, etc.

[0024] In a seventh aspect of the invention, there is provided a detection kit comprising a container and a reagent or combination of reagents as described above located in the container; preferably, each reagent is located in a separate container.

[0025] In one preferred embodiment, the kit further comprises bisulfite, DNA purification reagents, DNA extraction reagents, PCR amplification reagents and / or a user manual indicating the detection procedure steps and result criteria.

[0026] In an eighth aspect of the present invention there is provided a method for detecting a methylation profile of a sample in vitro comprising: (i) providing a sample and extracting nucleic acid; and (ii) detecting the modification status of CpG sites of a target sequence in the nucleic acid of (i), wherein said target sequence is a polynucleotide as described in the first aspect or a polynucleotide as described in the second aspect converted therefrom.

[0027] In a preferred embodiment, in step (3), the analysis method includes pyrosequencing, bisulfite sequencing, methylation chip, qPCR, digital PCR, next generation sequencing, third generation sequencing, whole genome methylation sequencing, DNA enrichment detection, Reduced Representation Bisulfite Sequencing (RRBS) technology, HPLC, MassArray, methylation specific PCR (MSP), or a combination thereof, and an in vitro detection method and an in vivo tracer detection method of a gene group combined with a part or all of the methylation sites in the sequence shown in SEQ ID NO: 1. In addition, other methylation detection methods and methylation detection methods newly developed in the future can also be applied to the present invention.

[0028] In another preferred embodiment, step (ii) comprises: (1) treating the product of (i) so as to convert unmodified cytosines therein to uracils; preferably, said modifications comprise a 5-methylation modification, a 5-hydroxymethylation modification, a 5-formylation modification or a 5-carboxylation modification; preferably treating the nucleic acid described in step (i) with bisulfite; and (2) analyzing the modification status of said target sequence in the nucleic acid treated in (1).

[0029] In another preferred embodiment, the abnormal methylation profile means that C in the polynucleotide CpG is highly methylated.

[0030] In another preferred embodiment, the above methylation profiling method is not intended to directly obtain a diagnosis of a disease and is not a diagnostic method.

[0031] In a ninth aspect of the present invention, there is provided a tumor diagnostic kit which comprises a primer pair designed based on the sequence shown in the first or second aspect of the present invention and a gene panel or gene group containing the sequence, and which obtains characteristics of normal cells and tumor cells by detecting DNA methylation status.

[0032] Based on the disclosure herein, other aspects of the invention will be apparent to those of ordinary skill in the art. [Brief description of the drawings]

[0033] [Figure 1] BSP validation of methylation levels between lung cancer cells and normal lung cells for the 001-040 methylation site in the SEQ ID NO: 1 region. The dark boxes in the figure indicate the presence of methylation. [Diagram 2] BSP validation of methylation levels between lung cancer cells and normal lung cells for the 041-077 methylation site in the SEQ ID NO: 1 region. The dark boxes in the figure indicate the presence of methylation. [Diagram 3] BSP validation of methylation levels between lung cancer cells and normal lung cells at the 078-114 methylation site in the SEQ ID NO: 1 region. The dark boxes in the figure indicate the presence of methylation. [Figure 4] BSP validation of methylation levels between lung cancer cells and normal lung cells at 115-153 methylation site in SEQ ID NO: 1 region. Dark boxes in the figure indicate the presence of methylation. [Diagram 5] BSP validation of methylation levels between lung cancer cells and normal lung cells at 154-191 methylation site in SEQ ID NO: 1. Dark boxes in the figure indicate the presence of methylation. [Figure 6] Comparison of STAMP-EP8 methylation levels in leukemia clinical samples, non-cancerous tissue samples, and cancerous tissue samples. [Figure 7] Comparison of STAMP-EP8 methylation levels in paraganglioma samples and cancer tissue samples with those in breast cancer clinical samples. [Figure 8] Comparison of STAMP-EP8 methylation levels in paraganglioma and cancer tissue samples versus colorectal cancer clinical samples. [Figure 9] Comparison of STAMP-EP8 methylation levels in esophageal cancer clinical samples, paraganglioma samples, and cancer tissue samples. [Figure 10] Comparison of STAMP-EP8 methylation levels in paraganglioma samples and cancer tissue samples with those in liver cancer clinical samples. [Figure 11] Comparison of STAMP-EP8 methylation levels in lung cancer clinical samples, paraganglioma samples, and cancer tissue samples. [Figure 12] , Comparison of STAMP-EP8 methylation levels in paraganglioma samples and cancer tissue samples with pancreatic cancer clinical samples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] As a result of the inventors' research into tumor markers, through extensive research and screening, they have provided a versatile DNA methylation tumor marker STAMP (Specific Tumor Aligned Methylation of Pan-cancer), which is hypomethylated in normal tissues and hypermethylated in tumor tissues, and can be used as a basis for the detection of clinical tumors and the design of tumor diagnostic reagents.

[0035] term As used herein, "isolated" refers to isolating a material from its original environment (if it is a naturally occurring material, the original environment is the natural environment). For example, polynucleotides and polypeptides that are naturally occurring in living cells are not isolated or purified, but the same polynucleotide or polypeptide is isolated or purified when it is separated from other materials with which it coexists in the natural state.

[0036] As used herein, a "sample" or "specimen" includes any material obtained from an individual or isolated tissue, cell, or body fluid (such as plasma) suitable for detection of DNA methylation status. For example, the samples referred to include, but are not limited to, tissue samples, paraffin-embedded samples, blood samples, pleural fluid samples, bronchoalveolar lavage fluid samples, peritoneal fluid and lavage fluid samples, bile samples, stool samples, urine samples, saliva samples, cerebrospinal fluid samples, cell smear samples, cervical smear or brush samples, tissue and cell biopsy samples.

[0037] As used herein, "hypermethylation" refers to the presence of high methylation, hydroxymethylation, formylation or carboxylation modifications of CpGs in a gene sequence. For example, in terms of methylation-specific PCR (MSP) analysis, in a PCR reaction using methylation-specific primers, a positive PCR result means that the DNA (gene) region being tested is in a hypermethylated state. For example, in the case of real-time quantitative methylation-specific PCR, the determination of the hypermethylation state can be analyzed for statistical differences based on the relative value of the methylation state of a control sample.

[0038] Genetic markers In order to find a target useful for diagnosing tumors, the present inventors have conducted extensive and detailed research and identified a target called STAMP-EP8. Since the methylation status of the STAMP-EP8 gene sequence region is significantly different between tumor tissues and non-tumor tissues, the presence of abnormal hypermethylation status in the STAMP-EP8 gene sequence region can determine that the subject is in a high-risk group for cancer. Furthermore, the significant difference between tumor tissues and non-tumor tissues presented by STAMP-EP8 is widely present in various types of tumors, including solid tumors and non-solid tumors.

[0039] The present invention also provides an isolated polynucleotide, which has a nucleotide sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 3 (a sequence reverse-complementary to SEQ ID NO: 1), and in tumor cells, 5-methylcytosine (5mC) is generated at multiple 5'-CpG-3' base C positions in the polynucleotide sequence. The present invention also includes a fragment of a polynucleotide having a nucleotide sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 3, which has at least one (e.g., 2 to 191, more specifically, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190) methylated CpG site. The above polynucleotide or fragment may be used to design a detection reagent or detection kit.

[0040] In some specific examples of the present invention, the above polynucleotide fragment is, for example, a fragment containing bases 281-309 of SEQ ID NO: 1 (containing CpG sites 017-020). Antisense strands of the above fragments can also be used. These fragments are examples of preferred embodiments of the present invention; other fragments can also be selected according to the information provided by the present invention.

[0041] The present invention also includes a gene panel or a group of genes comprising the nucleotide sequence or sequence fragment shown in SEQ ID NO: 1 or SEQ ID NO: 2. For the above gene panel or group of genes, the detection of DNA methylation status also provides characteristics of normal and tumor cells.

[0042] The above polynucleotides can be used as important regions of the genome to analyze the methylation status, which can be analyzed by various techniques known in the art. Any technique that can be used to analyze the methylation status can be applied to the present invention.

[0043] After treatment of the above polynucleotide with bisulfite, unmethylated cytosines are converted to uracils and methylated cytosines remain unchanged.

[0044] The present invention also provides polynucleotides obtained by treating the above polynucleotides (including the complementary strand (antisense strand)) with bisulfite, including the polynucleotide having the nucleotide sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. These polynucleotides may be used in the design of detection reagents or detection kits.

[0045] The present invention also includes a polynucleotide fragment obtained by treating the above polynucleotide or its antisense strand with bisulfite, provided that there is at least one (e.g., 2 to 191, more specifically, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 90, 110, 130, 150, 170, 180, 190) methylated CpG site. The number of each CpG site in the antisense strand corresponding to the sense strand can be easily obtained according to the contents provided by the present invention.

[0046] Detection Reagents and Kits Based on the new findings of the present invention, a detection reagent designed based on the polynucleotide sequence is also provided for detecting the methylation profile of polynucleotides in a sample in vitro. Any method and reagent for detecting a defined genomic sequence, its mutation and methylation status known in the art can be applied to the present invention.

[0047] The present invention also provides a method for preparing a tumor detection reagent, comprising: providing the above-mentioned polynucleotide; using the full length or a fragment of the above-mentioned polynucleotide as a target sequence; and designing a detection reagent for specifically detecting the target sequence; provided that the above-mentioned target sequence contains at least one methylated CpG site.

[0048] Detection reagents described in the present invention include, but are not limited to, primers, probes, and the like.

[0049] The above reagent is, for example, a primer pair, and when the sequence of the polynucleotide is known, the design of the primer is known to those skilled in the art, and the two primers flank a specific sequence of the target gene to be amplified (including a CpG sequence, in which the complementary CpG targets the original methylated gene region, and the complementary TpG targets the original demethylated gene region). According to the new discovery of the present invention, for the CpG sites at different positions of the above target sequence or their combinations, those skilled in the art can design various primers or probes or other types of detection reagents, which should be understood to be included in the technical proposal of the present invention. In a preferred embodiment of the present invention, the above primers are selected from the group consisting of primers shown in SEQ ID NOs: 5 and 6, which are capable of obtaining an amplification product containing CpG sites 001-040 of SEQ ID NO:1; primers shown in SEQ ID NOs: 7 and 8, which are capable of obtaining an amplification product containing CpG sites 041-077 of SEQ ID NO:1; primers shown in SEQ ID NOs: 9 and 10, which are capable of obtaining an amplification product containing CpG sites 078-114 of SEQ ID NO:1; primers shown in SEQ ID NOs: 11 and 12, which are capable of obtaining an amplification product containing CpG sites 115-153 of SEQ ID NO:1; primers shown in SEQ ID NOs: 13 and 14, which are capable of obtaining an amplification product containing CpG sites 154-191 of SEQ ID NO:1; or primers shown in SEQ ID NOs: 15 and 16, which are capable of obtaining an amplification product containing CpG sites 021-024 of SEQ ID NO:1.

[0050] The above reagents may be a combination of reagents (primer combination), which contains multiple groups of primers and can amplify multiple of the above polynucleotides separately.

[0051] The present invention also provides a kit for detecting a methylation profile of a polynucleotide in a sample in vitro, the kit comprising a container and the above-described primer pair located in the container.

[0052] The above kit may further include various reagents necessary for DNA extraction, DNA purification, PCR amplification, and the like.

[0053] In addition, the above kit may include a user manual showing the detection operation steps and result judgment criteria for convenient use by those skilled in the art.

[0054] Detection Method The methylation profile of a polynucleotide can be measured by existing techniques (eg, methylation specific PCR (MSP) or real-time quantitative methylation specific PCR, Methylight) or other techniques under development and to be developed.

[0055] Quantitative methylation specific PCR (QMSP) can also be used to detect methylation levels. This method is based on continuous optical monitoring of fluorescent PCR, which is more sensitive than the MSP method. It has high throughput and avoids the use of electrophoresis to analyze the results.

[0056] Other techniques that can be used include conventional methods in the art, such as pyrosequencing, bisulfite sequencing, qPCR, next generation sequencing, whole genome methylation sequencing, DNA enrichment detection, Reduced Representation Bisulfite Sequencing (RRBS) technology, HPLC, and combined gene group detection. Based on the new disclosure of the present invention, it should be understood that these techniques known in the art as well as the techniques to be developed can all be applied to the present invention.

[0057] As a preferred embodiment of the present invention, a method for detecting the methylation profile of polynucleotide in a sample in vitro is also provided. The above method is based on the following principle: bisulfite can convert unmethylated cytosine to uracil, which is then converted to thymine in the subsequent PCR amplification process, while methylated cytosine remains unchanged; therefore, after treating polynucleotide with bisulfite, polynucleotide polymorphisms (SNPs), such as C / T, are generated at the methylated sites. Detecting the methylation profile of polynucleotide in a sample based on the above principle can effectively distinguish methylated cytosine from unmethylated cytosine.

[0058] The method described in the present invention comprises: (a) providing a sample and extracting genomic DNA; (b) treating the genomic DNA of step (a) with bisulfite to convert unmethylated cytosines in the genomic DNA to uracil; and (c) analyzing the genomic DNA treated in step (b) for the presence or absence of methylation profile abnormalities.

[0059] The method of the present invention may be used to (i) perform detection on a sample from a test subject and analyze whether the test subject has a tumor; (ii) distinguish high-risk groups for tumors. The above method may also be used in situations where the aim is not to obtain a direct disease diagnosis.

[0060] In a preferred embodiment of the present invention, DNA methylation is detected by PCR amplification and pyrosequencing, but those skilled in the art should understand that the actual application is not limited to this method, and other DNA methylation detection methods are also possible. The primers used for PCR amplification are not limited to those provided in the examples.

[0061] After genomic DNA is treated with bisulfite, unmethylated cytosine is converted to uracil, and then converted to thymine in the subsequent PCR process, which reduces the complexity of genome sequence, making it more difficult to amplify a specific target fragment by PCR.Therefore, nested PCR amplification is preferably adopted, and two pairs of primers are designed on the outer and inner circumferences, and two PCR amplification reactions are carried out, and the first amplification product is used as the template for the second amplification, which can effectively improve the efficiency and specificity of amplification.However, it should be understood that the detection method available in the present invention is not limited to this.

[0062] Through research and validation on clinical samples, the method of the present invention has a very high accuracy when used in clinical tumor diagnosis. The present invention can be applied to the fields of tumor auxiliary diagnosis, treatment effect assessment, prognosis monitoring and the like, and has high clinical application value.

[0063] The present invention will be further described below with reference to specific examples. It should be understood that these examples are merely illustrative of the present invention and do not limit the scope of the present invention. Experimental methods in the following examples that do not specify specific conditions are usually carried out according to the general conditions described in J. Sambrook et al., Guide to Molecular Cloning, Third Edition, Science Press, 2002, or according to the conditions recommended by the manufacturer. EXAMPLES

[0064] Example 1: Nucleic acid sequences involved in the detection of STAMP-EP8 After repeated research and screening, the inventors obtained a tumor marker STAMP-EP8, the sequence of which is shown in SEQ ID NO: 1 (chr8:23562476-23565175, Human / hg19); where the underlined bases are methylated CpG sites, and the underlined numbers indicate the site numbers.

[0065] [ka] [ka]

[0066] The bisulfite treated sequence of SEQ ID NO:1 is as follows: SEQ ID NO:2 (wherein Y represents C or U):

[0067] [ka] [ka]

[0068] The reverse complement of the nucleotide sequence shown in SEQ ID NO:1 above is set forth in SEQ ID NO:3:

[0069] [ka]

[0070] The bisulfite treated sequence of SEQ ID NO:3 is as follows: SEQ ID NO:4 (wherein Y represents C or U):

[0071] [ka]

[0072] Example 2: Differences in methylation of STAMP-EP8 CpG sites between tumor and non-tumor cell lines - BSP-Bisulfite Sequencing PCR The steps of the bisulfite sequencing PCR are shown below: 1. Genomic DNA was extracted from lung cancer cell line A549 and normal lung cell line MRC5; 2. Genomic DNA extracted from lung cancer cell line A549 and normal lung cell line MRC5 were treated with bisulfite, respectively, and used as templates for subsequent PCR amplification; 3. Amplification primers (SEQ ID NO:5-14) were designed according to the sequence of SEQ ID NO:1 as shown in Table 1, and amplification was performed. 4. After PCR amplification, the specificity of the PCR fragments was detected by 2% agarose gel electrophoresis, the gel was cut to recover the target fragments, ligated and inserted into T vector, transformed into competent E. coli, and spread on plates. On the second day, clones were selected for sequencing, and more than 10 clones were selected from each fragment for Sanger sequencing.

[0073] [Table 1]

[0074] The BSP validation results of the methylation levels of the 001-040 methylation site in the region of SEQ ID NO:1 between lung cancer cells and normal lung cells are shown in Figure 1, which showed that the STAMP-EP8 methylation level in lung cancer cells was significantly higher than that in normal liver cells.

[0075] The BSP validation results of the methylation levels of the 041-077 methylation site in the region of SEQ ID NO:1 between lung cancer cells and normal lung cells are shown in Figure 2, which showed that the STAMP-EP8 methylation level in lung cancer cells was significantly higher than that in normal liver cells.

[0076] The BSP validation results of the methylation levels of the 078-114 methylation site in the region of SEQ ID NO:1 between lung cancer cells and normal lung cells are shown in Figure 3, which showed that the STAMP-EP8 methylation level in lung cancer cells was significantly higher than that in normal liver cells.

[0077] The BSP validation results of the methylation levels of the 115-153 methylation site in the region of SEQ ID NO:1 between lung cancer cells and normal lung cells are shown in Figure 4, which showed that the STAMP-EP8 methylation level in lung cancer cells was significantly higher than that in normal liver cells.

[0078] The BSP validation results of the methylation levels of the 154-191 methylation site in the region of SEQ ID NO:1 between lung cancer cells and normal lung cells are shown in Figure 5, which showed that the STAMP-EP8 methylation level in lung cancer cells was significantly higher than that in normal liver cells.

[0079] Example 3: Differences in methylation of STAMP-EP8 CpG sites between tumor and non-tumor cell lines - pyrosequencing The steps of the pyrosequencing method are shown below: 1. Obtain clinical samples: Obtain paraganglioma / non-cancerous-cancer tissue samples from clinics, paraganglioma / non-cancerous samples were the control group, and cancer tissue samples were the tumor detection experimental group; 2. DNA extraction: DNA was extracted from the experimental and control groups respectively; in this experiment, the phenol-chloroform extraction method was used, but not limited to this method; 3. Bisulfite treatment: The extracted DNA samples were treated with bisulfite and the procedure was strictly followed; in this experiment, we used ZYMO Research's EZDNA Methylation-Gold Kit, item number D5006, but it is not limited to this kit; 4. Primer design: Based on the characteristics of SEQ ID NO:1, which is the STAMP-EP8 sequence, PCR amplification primers and pyrosequencing primers were designed; the methylation values ​​of the CpG sites of 021-024 were detected, and the PCR primer amplification sequences, pyrosequencing primer sequences, pyrosequencing machine detection sequences and detection sites were shown in SEQ ID NOs 15-18 as representatives of the STAMP-EP8 methylation values ​​(Table 2); 5. PCR amplification and agarose gel electrophoresis: The bisulfite-treated samples were used as templates for PCR, PCR amplification was performed, and the amplified products were identified by agarose gel electrophoresis to determine the specificity of PCR amplification; 6. Pyrosequencing: detected by QIAGEN company PyroMark Q96 ID pyrosequencer, operated strictly according to the steps in the user manual; 7. Calculation of the methylation value of STAMP-EP8: Pyrosequencing can detect the methylation value of each CpG site in the target region independently; the average methylation value of all CpG sites was calculated as the methylation value of STAMP-EP8 in the sample; 8. Analysis of results: STAMP-EP8 methylation levels were compared between the paraganglioma / non-cancerous control group and the tumor experimental group.

[0080] [Table 2]

[0081] Example 4: Leukemia - Clinical sample validation - Pyrosequencing Eight non-leukemic bone marrow smear samples obtained from clinical trials were used as the control group, and eight leukemic bone marrow smear samples were used as the experimental group. The STAMP-EP8 methylation levels of the control group and the experimental group were compared using the pyrosequencing step described in Example 3 above.

[0082] The results, as shown in FIG. 6, show that in leukemia clinical samples, the methylation value of STAMP-EP8 in the experimental group is significantly higher than that in non-cancerous tissues.

[0083] Example 5: Breast Cancer - Clinical Sample Validation - Pyrosequencing Five clinically obtained breast paraganglioma samples were used as the control group, and five breast cancer tissue samples were used as the experimental group. The STAMP-EP8 methylation levels of the control group and the experimental group were compared using the pyrosequencing step described in Example 3 above.

[0084] The results are shown in FIG. 7, in which the methylation level of STAMP-EP8 in the breast cancer clinical samples in the experimental group was significantly higher than that in the paraganglioma tissues.

[0085] Example 6: Colorectal cancer - validation of clinical case samples - pyrosequencing method Eight clinically obtained colorectal cancer paraganglioma samples were used as the control group, and eight colorectal cancer samples were used as the experimental group, and the methylation levels of STAMP-EP8 were analyzed by the pyrosequencing step of Example 3.

[0086] The results are shown in Figure 8, in which the methylation level of STAMP-EP8 in the clinical colorectal cancer samples from the experimental group was significantly higher than that in the paraganglioma tissues.

[0087] Example 7: Esophageal cancer - Verification of clinical case samples - Pyrosequencing method Ten esophageal cancer paraganglioma samples obtained from clinical trials were used as the control group, and ten esophageal cancer samples were used as the experimental group. The methylation levels of STAMP-EP8 were analyzed by the pyrosequencing step of Example 3.

[0088] The results are shown in FIG. 9, in the esophageal cancer clinical samples, the methylation value of STAMP-EP8 in the experimental group was significantly higher than that in the paraganglioma tissues.

[0089] Example 8: Liver cancer - verification of clinical case samples - pyrosequencing method Eight clinically obtained liver cancer paraganglioma samples were used as the control group, and eight liver cancer samples were used as the experimental group. The methylation levels of STAMP-EP8 were analyzed by the pyrosequencing step of Example 3.

[0090] The results are shown in FIG. 10, in which the methylation value of STAMP-EP8 in the liver cancer clinical samples in the experimental group was significantly higher than that in the paraganglioma tissues.

[0091] Example 9: Lung cancer - validation of clinical case samples - pyrosequencing method Four lung cancer paraganglioma samples obtained from clinical trials were used as the control group, and four lung cancer samples were used as the experimental group. The methylation levels of STAMP-EP8 were analyzed by the pyrosequencing step of Example 3.

[0092] The results are shown in FIG. 11, in which the methylation level of STAMP-EP8 in the experimental group of lung cancer clinical samples was significantly higher than that in the paraganglioma tissues.

[0093] Example 10: Pancreatic cancer - Clinical sample validation - Pyrosequencing Four pancreatic cancer paraganglioma samples obtained from clinical trials were used as the control group, and four pancreatic cancer samples were used as the experimental group. The methylation levels of STAMP-EP8 were analyzed by the pyrosequencing step of Example 3.

[0094] The results are shown in FIG. 12, in pancreatic cancer clinical samples, the methylation value of STAMP-EP8 in the experimental group was significantly higher than that in paraganglioma tissues.

[0095] All references mentioned in this application are incorporated herein by reference as if each reference were incorporated solely by reference. It should be understood that based on the above disclosure of the present invention, one skilled in the art may make various changes or modifications to the present invention, and equivalents thereof are also included within the scope defined in the claims appended hereto.

Claims

1. 1. A method for preparing a reagent for tumor detection, comprising:

2. Step (i) of providing an isolated polynucleotide, comprising: The isolated polynucleotide comprises: (a) a polynucleotide consisting of the nucleotide sequence set forth in SEQ ID NO:1; (b) a fragment of the polynucleotide of (a), which comprises the sequence shown in positions 204 to 223 or 1 to 478 of SEQ ID NO: 1; and / or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b); Step (i) comprising: (ii) designing a detection reagent for specifically detecting the modification status of a CpG site in a target sequence, the entire length or a fragment of the polynucleotide being used as a target sequence, the target sequence being a fragment of the sequence shown in positions 204 to 223 or 1 to 478 of SEQ ID NO: 1; Including, the modification is a 5-methylation modification, The tumor detection reagent is capable of detecting multiple tumors. method.

2. The plurality of tumors include tumors of the digestive system, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, and gallbladder cancer; tumors of the gynecological and reproductive system, including breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, and penile cancer; tumors of the blood system, including leukemia, lymphoma, and multiple myeloma; tumors of the respiratory system, including lung cancer and pleurioma; tumors of the nervous system, including glioma, neuroblastoma, and meningioma; tumors of the head and neck, including oral cancer, tongue cancer, laryngeal cancer, and nasopharyngeal cancer; tumors of the urinary system, including kidney cancer and bladder cancer; tumors of the skin and other systems, including skin cancer, melanoma, osteosarcoma, liposarcoma, and thyroid cancer, The method of claim 1.

3. the detection reagent comprises a primer, The primer is A primer shown in SEQ ID NO:5 and a primer shown in SEQ ID NO:6; A primer set forth in SEQ ID NO:7 and a primer set forth in SEQ ID NO:8; A primer set forth in SEQ ID NO:9 and a primer set forth in SEQ ID NO:10; A primer set forth in SEQ ID NO:11 and a primer set forth in SEQ ID NO:12; A primer set forth in SEQ ID NO:13 and a primer set forth in SEQ ID NO:14; or A primer set forth in SEQ ID NO: 15 and a primer set forth in SEQ ID NO:

16. The method according to claim 1 or 2.

4. The method according to any one of claims 1 to 3, further comprising treating the isolated polynucleotide such that in step (i), cytosine C at the modified CpG site is left unchanged and unmodified cytosine is converted to T or U.

5. (d) a polynucleotide consisting of the nucleotide sequence set forth in SEQ ID NO:2 or SEQ ID NO:4; (e) a fragment of the polynucleotide of (d), comprising the sequence shown in positions 2478 to 2497 of SEQ ID NO: 4 or 3, or positions 2223 to 2700 of SEQ ID NO: 4 or 3; 5. The method of claim 4, comprising:

6. Use of a reagent for detecting a methylation profile of a CpG site of an isolated polynucleotide in the preparation of a reagent or kit for detecting a tumor, comprising: The isolated polynucleotide comprises: (a) a polynucleotide consisting of the nucleotide sequence set forth in SEQ ID NO:1; (b) a fragment of the polynucleotide of (a), which comprises the sequence shown in positions 204 to 223 or 1 to 478 of SEQ ID NO: 1; and / or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b); Including, The isolated polynucleotide comprises a fragment of the sequence shown in positions 204-223 or 1-478 of SEQ ID NO:1; The tumor detection reagent is capable of detecting a plurality of tumors, the plurality of tumors being: tumors of the digestive system, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, and gallbladder cancer; tumors of the gynecological and reproductive system, including breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, and penile cancer; tumors of the blood system, including leukemia, lymphoma, and multiple myeloma; tumors of the respiratory system, including lung cancer and pleurioma; tumors of the nervous system, including glioma, neuroblastoma, and meningioma; tumors of the head and neck, including oral cancer, tongue cancer, laryngeal cancer, and nasopharyngeal cancer; tumors of the urinary system, including kidney cancer and bladder cancer; tumors of the skin and other systems, including skin cancer, melanoma, osteosarcoma, liposarcoma, and thyroid cancer, use.

7. The detection reagent comprises a primer, The primer is A primer shown in SEQ ID NO:5 and a primer shown in SEQ ID NO:6; A primer set forth in SEQ ID NO:7 and a primer set forth in SEQ ID NO:8; A primer set forth in SEQ ID NO:9 and a primer set forth in SEQ ID NO:10; A primer set forth in SEQ ID NO:11 and a primer set forth in SEQ ID NO:12; A primer set forth in SEQ ID NO:13 and a primer set forth in SEQ ID NO:14; or The use according to claim 6, characterized in that the primers are those shown in SEQ ID NO:15 and SEQ ID NO:

16.

8. 8. The use according to claim 6 or 7, characterized in that the tumor samples comprise tissue samples, paraffin-embedded samples, blood samples, pleural fluid samples, bronchoalveolar lavage fluid samples, ascites and lavage fluid samples, bile samples, stool samples, urine samples, saliva samples, sputum samples, cerebrospinal fluid samples, cell smear samples, cervical smear or brush samples, tissue and cell biopsy samples.

9. The method of claim 1 or 2, wherein the detection reagent comprises a probe.

10. A tumor detection reagent or combination of reagents for specifically detecting the modification status of a CpG site in a target sequence, the target sequence comprising a full-length or fragment of a polynucleotide, The polynucleotide is (a) a polynucleotide consisting of the nucleotide sequence set forth in SEQ ID NO:1; (b) a fragment of the polynucleotide of (a), which comprises the sequence shown in positions 204 to 223 or 1 to 478 of SEQ ID NO: 1; and / or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b); Including, The isolated polynucleotide comprises a fragment of the sequence shown in positions 204-223 or 1-478 of SEQ ID NO: 1; The detection reagent comprises a primer, The primer is A primer shown in SEQ ID NO:5 and a primer shown in SEQ ID NO:6; A primer shown in SEQ ID NO:7 and a primer shown in SEQ ID NO:8; A primer shown in SEQ ID NO:9 and a primer shown in SEQ ID NO:10; A primer shown in SEQ ID NO:11 and a primer shown in SEQ ID NO:12; A primer set forth in SEQ ID NO:13 and a primer set forth in SEQ ID NO:14; or A primer set forth in SEQ ID NO: 15 and a primer set forth in SEQ ID NO: 16, the modification is a 5-methylation modification; A reagent or combination of reagents for tumor detection to specifically detect the modification status of CpG sites.

11. A tumor detection reagent or combined reagent for specifically detecting the modification status of CpG sites as described in claim 10, characterized in that the detection reagent or combined reagent targets a gene sequence including the target sequence, and the gene sequence includes a gene panel or gene group.

12. The tumor detection reagent or combination of reagents for specifically detecting the modification status of CpG sites according to claim 10, characterized in that the detection reagent or combination of reagents further comprises a probe.

13. Use of a tumor detection reagent or a combination of reagents for specifically detecting the modification status of CpG sites according to any one of claims 10 to 12 for preparing a kit for tumor detection.

14. 14. The use according to claim 13, wherein the tumor comprises hematological tumors including leukemia, lymphoma, multiple myeloma; gynecological and reproductive tumors including breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, penile cancer; digestive tumors including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, gallbladder cancer; respiratory tumors including lung cancer, pleurioma; nervous tumors including glioma, neuroblastoma, meningioma; head and neck tumors including oral cancer, tongue cancer, laryngeal cancer, nasopharyngeal cancer; urinary tumors including kidney cancer, bladder cancer, skin cancer, melanoma, osteosarcoma, liposarcoma, thyroid cancer.

15. A container, and a tumor detection reagent or a combination of reagents for specifically detecting the modification status of a CpG site according to any one of claims 10 to 12, which is contained in the container. A detection kit comprising:

16. (iii) analyzing the modification status of the CpG site; The method of any one of claims 1 to 5, further comprising:

17. In the step (iii), the modification status of the CpG site is methylation, and analyzing the methylation status; The method of claim 16, wherein the analyzing method comprises pyrosequencing, bisulfite sequencing, methylation chip, qPCR, digital PCR, next generation sequencing, third generation sequencing, whole genome methylation sequencing, DNA enrichment detection, Reduced Representation Bisulfite Sequencing (RRBS) technology, HPLC, MassArray, methylation specific PCR, or a combination thereof, and an in vitro detection method and an in vivo tracer detection method of a combination of gene groups of some or all of the methylation sites in the sequence shown in SEQ ID NO:

1.

18. The step (ii) (1) treating the product of step (i) with bisulfite to convert unmodified cytosines in the product of step (i) to uracils; (2) analyzing the modification status of the target sequence in the nucleic acid treated in (1); 3. The method according to claim 1 or 2, comprising:

Citation Information

Patent Citations

  • Epigenetic Markers Of Colorectal Cancers And Diagnostic Methods Using The Same

    CN105886657A

  • Tumor marker STAMP-EP2 based on methylated modification

    CN108866191A

  • Tumor marker STAMP-EP1 based on methylated modification

    CN108866192A

  • Methylated modification based tumor marker STAMP (specific tumor aligned methylation of pan-cancer)-EP4

    CN109371138A

  • Tumor marker STAMP-EP5 based on methylation modification

    CN109456968A